Alloreactive CD8 T cells rescued from apoptosis during co-stimulation blockade by Toll-like receptor stimulation remain susceptible to Fas-induced cell death

Immunology

Volumn 138, Issue 4, 2013, Pages 322-332

  Priyadharshini, Bhavana ^a   Thornley, Thomas B ^a   Daniels, Keith A ^b   Cuthbert, Amy ^b   Welsh, Raymond M ^b   Greiner, Dale L ^b   Brehm, Michael A ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Apoptosis; T cells; Tolerance

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; CD40 LIGAND; CD69 ANTIGEN; FAS ANTIGEN; FAS LIGAND; INTERLEUKIN 2 RECEPTOR ALPHA; TOLL LIKE RECEPTOR;

ALLOIMMUNITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BONE MARROW; CD8+ T LYMPHOCYTE; CELL DEATH; CHIMERA; CONTROLLED STUDY; FEMALE; HUMAN; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIBODIES; ANTIGENS, CD; ANTIGENS, CD95; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; APOPTOSIS; CD40 LIGAND; CD8-POSITIVE T-LYMPHOCYTES; FAS LIGAND PROTEIN; GENE EXPRESSION REGULATION; IMMUNE TOLERANCE; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; LECTINS, C-TYPE; LIPOPOLYSACCHARIDES; LYMPHOCYTE ACTIVATION; MALE; MICE; MICE, INBRED C57BL; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTORS;

EID: 84874968418     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/imm.12044     Document Type: Article

References (52)

1. Clarkson MR, Sayegh MH. T-cell costimulatory pathways in allograft rejection and tolerance. Transplantation 2005; 80:555-63.
2. Priyadharshini B, Greiner DL, Brehm MA. T-cell activation and transplantation tolerance. Transplant Rev (Orlando) 2011; 26:212-22.
3. Sayegh MH, Akalin E, Hancock WW, Russell ME, Carpenter CB, Linsley PS, Turka LA. CD28-B7 blockade after alloantigenic challenge in vivo inhibits Th1 cytokines but spares Th2. J Exp Med 1995; 181:1869-74.
4. Turka LA, Linsley PS, Lin H et al. T-cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo. Proc Natl Acad Sci U S A 1992; 89:11102-5.
5. Miller DM, Thornley TB, Pearson T et al. TLR agonists prevent the establishment of allogeneic hematopoietic chimerism in mice treated with costimulation blockade. J Immunol 2009; 182:5547-59.
6. Thornley TB, Brehm MA, Markees TG et al. TLR agonists abrogate costimulation blockade-induced prolongation of skin allografts. J Immunol 2006; 176:1561-70.
7. Thornley TB, Phillips NE, Beaudette-Zlatanova BC et al. Type 1 IFN mediates cross-talk between innate and adaptive immunity that abrogates transplantation tolerance. J Immunol 2007; 179:6620-9.
8. Xu H, Elster E, Batty D et al. Effects of dose and duration of anti-CD154 antibody therapy in preventing renal allograft rejection in a nonhuman primate model. Transplant Proc 2001; 33:223-4.
9. Xu H, Tadaki DK, Elster EA et al. Humanized anti-CD154 antibody therapy for the treatment of allograft rejection in nonhuman primates. Transplantation 2002; 74:940-3.
10. + T cells and prolonged graft survival in a CTLA4-dependent manner. J Immunol 2000; 164:512-21.
11. Wells AD, Li XC, Li Y et al. Requirement for T-cell apoptosis in the induction of peripheral transplantation tolerance. Nat Med 1999; 5:1303-7.
12. Li XC, Demirci G, Ferrari-Lacraz S, Groves C, Coyle A, Malek TR, Strom TB. IL-15 and IL-2: a matter of life and death for T cells in vivo. Nat Med 2001; 7:114-18.
13. Thompson MR, Kaminski JJ, Kurt-Jones EA, Fitzgerald KA. Pattern recognition receptors and the innate immune response to viral infection. Viruses 2011; 3:920-40.
14. LaRosa DF, Rahman AH, Turka LA. The innate immune system in allograft rejection and tolerance. J Immunol 2007; 178:7503-9.
15. + T-cell deletion induced by costimulation blockade. J Surg Res 2000; 93:63-9.
16. Wang T, Chen L, Ahmed E et al. Prevention of allograft tolerance by bacterial infection with Listeria monocytogenes. J Immunol 2008; 180:5991-9.
17. Adams AB, Williams MA, Jones TR et al. Heterologous immunity provides a potent barrier to transplantation tolerance. J Clin Invest 2003; 111:1887-95.
18. Brehm MA, Markees TG, Daniels KA, Greiner DL, Rossini AA, Welsh RM. Direct visualization of cross-reactive effector and memory allo-specific CD8 T cells generated in response to viral infections. J Immunol 2003; 170:4077-86.
19. Chen L, Ahmed E, Wang T, Wang Y, Ochando J, Chong A, Alegre M-L. TLR signals promote IL-6/IL-17-dependent transplant rejection. J Immunol 2009; 182:6217.
20. Porrett PM, Yuan X, LaRosa DF et al. Mechanisms underlying blockade of allograft acceptance by TLR ligands. J Immunol 2008; 181:1692-9.
21. Quezada SA, Bennett K, Blazar BR, Rudensky AY, Sakaguchi S, Noelle RJ. Analysis of the underlying cellular mechanisms of anti-CD154-induced graft tolerance: the interplay of clonal anergy and immune regulation. J Immunol 2005; 175:771-9.
22. + T cells in a tolerant environment depend on timing and place of antigen exposure. Am J Transplant 2012; 12:576-89.
23. Miller DM, Rossini AA, Greiner DL. Role of innate immunity in transplantation tolerance. Crit Rev Immunol 2008; 28:403-39.
24. Iwakoshi NN, Markees TG, Turgeon N et al. Skin allograft maintenance in a new synchimeric model system of tolerance. J Immunol 2001; 167:6623-30.
25. Bouillet P, O'Reilly LA. CD95, BIM and T cell homeostasis. Nat Rev Immunol 2009; 9:514-19.
26. Schonrich G, Kalinke U, Momburg F et al. Down-regulation of T cell receptors on self-reactive T cells as a novel mechanism for extrathymic tolerance induction. Cell 1991; 65:293-304.
27. Tafuri A, Alferink J, Moller P, Hammerling GJ, Arnold B. T cell awareness of paternal alloantigens during pregnancy. Science 1995; 270:630-3.
28. Langlois RA, Legge KL. Plasmacytoid dendritic cells enhance mortality during lethal influenza infections by eliminating virus-specific CD8 T cells. J Immunol 2010; 184:4440-6.
29. + thymocytes by the anti-Fas antibody. J Exp Med 1995; 181:485-91.
30. Oehen S, Brduscha-Riem K, Oxenius A, Odermatt B. A simple method for evaluating the rejection of grafted spleen cells by flow cytometry and tracing adoptively transferred cells by light microscopy. J Immunol Methods 1997; 207:33-42.
31. Brehm MA, Mangada J, Markees TG et al. Rapid quantification of naive alloreactive T cells by TNF-α production and correlation with allograft rejection in mice. Blood 2007; 109:819-26.
32. Barber DL, Wherry EJ, Ahmed R. Cutting edge: rapid in vivo killing by memory CD8 T cells. J Immunol 2003; 171:27-31.
33. Sun S, Zhang X, Tough DF, Sprent J. Type I interferon-mediated stimulation of T cells by CpG DNA. J Exp Med 1998; 188:2335-42.
34. Brehm MA, Daniels KA, Welsh RM. Rapid production of TNF-α following TCR-engagement of naïve CD8 T cells. J Immunol 2005; 175:5043-9.
35. Li XC, Wells AD, Strom TB, Turka LA. The role of T cell apoptosis in transplantation tolerance. Curr Opin Immunol 2000; 12:522-7.
36. Trambley J, Lin A, Elwood E et al. FasL is important in costimulation blockade-resistant skin graft rejection. Transplantation 2001; 71:537-43.
37. Wagener ME, Konieczny BT, Dai Z, Ring GH, Lakkis FG. Alloantigen-driven T cell death mediated by Fas ligand and tumor necrosis factor-α is not essential for the induction of allograft acceptance. Transplantation 2000; 69:2428-32.
38. Xie L, Shi W, Guo P. Roles of tumor necrosis factor-related apoptosis-inducing ligand in corneal transplantation. Transplantation 2003; 76:1556-9.
39. Ferguson TA, Griffith TS. The role of Fas ligand and TNF-related apoptosis-inducing ligand (TRAIL) in the ocular immune response. Chem Immunol Allergy 2007; 92:140-54.
40. Hughes PD, Belz GT, Fortner KA, Budd RC, Strasser A, Bouillet P. Apoptosis regulators Fas and Bim cooperate in shutdown of chronic immune responses and prevention of autoimmunity. Immunity 2008; 28:197-205.
41. Hutcheson J, Scatizzi JC, Siddiqui AM et al. Combined deficiency of proapoptotic regulators Bim and Fas results in the early onset of systemic autoimmunity. Immunity 2008; 28:206-17.
42. + T cell contraction. Immunity 2008; 28:218-30.
43. Alderson MR, Tough TW, Davis-Smith T et al. Fas ligand mediates activation-induced cell death in human T lymphocytes. J Exp Med 1995; 181:71-7.
44. Li JH, Rosen D, Sondel P, Berke G. Immune privilege and FasL: two ways to inactivate effector cytotoxic T lymphocytes by FasL-expressing cells. Immunology 2002; 105:267-77.
45. Askenasy N, Yolcu ES, Yaniv I, Shirwan H. Induction of tolerance using Fas ligand: a double-edged immunomodulator. Blood 2005; 105:1396-404.
46. Lau HT, Yu M, Fontana A, Stoeckert CJ Jr. Prevention of islet allograft rejection with engineered myoblasts expressing FasL in mice. Science 1996; 273:109-12.
47. Shi W, Chen M, Xie L. Prolongation of corneal allograft survival by CTLA4-FasL in a murine model. Graefes Arch Clin Exp Ophthalmol 2007; 245:1691-7.
48. Yolcu ES, Gu X, Lacelle C, Zhao H, Bandura-Morgan L, Askenasy N, Shirwan H. Induction of tolerance to cardiac allografts using donor splenocytes engineered to display on their surface an exogenous fas ligand protein. J Immunol 2008; 181:931-9.
49. Kawai T, Andrews D, Colvin RB, Sachs DH, Cosimi AB. Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand. Nat Med 2000; 6:114.
50. Robles-Carrillo L, Meyer T, Hatfield M et al. Anti-CD40L immune complexes potently activate platelets in vitro and cause thrombosis in FCGR2A transgenic mice. J Immunol 2010; 185:1577-83.
51. Wu Z, Bensinger SJ, Zhang J et al. Homeostatic proliferation is a barrier to transplantation tolerance. Nat Med 2004; 10:87-92.
52. Yang J, Brook MO, Carvalho-Gaspar M et al. Allograft rejection mediated by memory T cells is resistant to regulation. Proc Natl Acad Sci USA 2007; 104:19954-9.